Trial Profile

Mechanism of Resistance to GNC-038, a Tetra-specific T Cell Engager, in Relapsed and Refractory Diffuse Large B-cell Lymphoma

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 02 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emfizatamab (Primary)
Indications Diffuse large B cell lymphoma
Focus Pharmacodynamics

Most Recent Events

26 Aug 2022 Planned End Date changed from 1 Apr 2024 to 1 Sep 2024.
26 Aug 2022 Planned primary completion date changed from 1 Apr 2023 to 1 Sep 2023.
17 Apr 2022 Planned End Date changed from 1 Oct 2023 to 1 Apr 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com